Subscribe to RSS



Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) Declares In-Line 4Q Loss – IDIX, GILD, CERS, MDVN, ARNA

Shares of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) surged about 2% on Friday as it loss of 17 cents a share in the Q4 of 2012 was a penny underneath the year-before loss and in-line with the Zacks Consensus anticipates.

The firm’s Q4 2012 revenues were $0.3M increased from ($0.7) million in the year-before period, but lower than the Zacks Consensus anticipates of $1M. Revenues in the year-earlier quarter suffered from a charge against revenues value $3.4M.

The firm reported that full-year 2012 adjusted net loss came in at 21 cents a share, lower than the year-before loss of 57 cents and the Zacks Consensus anticipates of a loss of 25 cents a share.

Shares of Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) opened at $4.18 with 133.88 million outstanding shares and touch its highest price of $4.33 of the day and then finished at $4.29 by scoring +1.90%, as in the whole session stocks gain volume of 694,142 shares which is lower than its average volume.

As the owner ship concerns stock institutional ownership remained 72.85% while insider ownership included 0.07%. The share capital of IDIX has 133.88 million outstanding shares amid them 100.24 million shares have been floated in market.

For investors focus on the performance of the stocks so the IDIX showed weekly behind performance of -5.51% which was maintained for the month at -7.14%. Correspondingly the negative performance for the quarter was remained -19.06% and if took notice on yearly performance that was -65.38% whereas the year to date performance halted at -11.55%.

As the moving toward the returns measures returns on Investment ratio is significant measure which investor should have in consideration, the IDIX return on investment was recorded as -16.76% as compare to its rivals has Gilead Sciences, Inc. (NASDAQ:GILD)’s ROI 16.27%, Cerus Corporation (NASDAQ:CERS)’s ROI -101.54%, Medivation, Inc. (NASDAQ:MDVN)’s ROI -9.98%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s ROI -42.64%.


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

Shares of BioFuel Energy Corp. (Nasdaq:BIOF) skyrocketed on Thursday’s market activity, currently trading for about $8.20, up $2.14 (or +35.30%), and 5,845,868 of its shares exchanged hands so far BioFuel Energy recently received a preliminary non-binding proposal, which suggested the company acquire acquire all of the equity interests in real-estate developer JBGL Capital and JBGL

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

Crown Equity Holdings Inc Surges on CRWE-PR network Achievement (OTCMKTS:CRWE)

With today’s stock market pullback in session, you can take a look at over-the-counter securities (OTC) – Crown Equity Holdings Inc ticker symbol (OTCMKTS:CRWE). Crown Equity Holdings Inc stock price has surged today as high as +13.64% Up 0.0009, currently at +6.06% Up 0.0004, just shy of 300K shares in play in the financial market

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.